Detalhe da pesquisa
1.
Relative vaccine effectiveness against COVID-19 hospitalisation in persons agedâ¯≥â¯65â¯years: results from a VEBIS network, Europe, October 2021 to July 2023.
Euro Surveill
; 29(1)2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38179626
2.
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
Euro Surveill
; 29(13)2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551095
3.
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Euro Surveill
; 29(8)2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390651
4.
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.
Euro Surveill
; 28(21)2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227299
5.
Epitweetr: Early warning of public health threats using Twitter data.
Euro Surveill
; 27(39)2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36177867
6.
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.
Euro Surveill
; 27(21)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35620997
7.
Developing a sentinel syndromic surveillance system using school-absenteeism data, example monitoring absences over the 2020 COVID-19 pandemic.
Epidemiol Infect
; 149: e248, 2021 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34749838
8.
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
Euro Surveill
; 26(29)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34296676
9.
Training for Foodborne Outbreak Investigations by Using Structured Learning Experience.
Emerg Infect Dis
; 26(1): 162-164, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31855547
10.
Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020.
Euro Surveill
; 25(10)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32183932
11.
Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.
Euro Surveill
; 24(8)2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808440
12.
Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons.
Euro Surveill
; 24(45)2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31718740
13.
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort.
Euro Surveill
; 24(48)2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796152
14.
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.
Euro Surveill
; 23(9)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29510782
15.
Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.
Euro Surveill
; 22(7)2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28230524
16.
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
Euro Surveill
; 21(7): pii=30139, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26924024
17.
I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
Euro Surveill
; 21(16)2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27124420
18.
Measuring the proportion of and reasons for asthma-related school absence in England.
Clin Exp Allergy
; 50(6): 752-755, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32080928
19.
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
Vaccine
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644077
20.
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Influenza Other Respir Viruses
; 18(4): e13292, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654485